Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 9, 2003. The report is a notification of changes in directors' interests in the company's Ordinary Shares rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and shareholding disclosures.
Material Changes
The primary material change disclosed is a transfer of shares within employee benefit structures:
- Transfer Date: April 7, 2003.
- Transferor: SmithKline Beecham Employee Benefit Trust.
- Transferee: Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust").
- Volume: 92,431,671 Ordinary Shares.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, two directors, Dr. J P Garnier and Mr. J D Coombe, hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding financial operations are mentioned in this text.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust post-transfer.
- Confirm the specific beneficial ownership percentages for Dr. J P Garnier and Mr. J D Coombe resulting from this trust transfer.
- Review the terms of the GSK Trust to understand the vesting or distribution conditions for the transferred shares.